OXBRYTA ® Helpline
Did you or a loved one experience extreme pain or death after using the Pfizer sickle cell disease drug OXBRYTA ®? You may qualify for financial compensation.
About OXBRYTA ®
In September 2024, drugmaker Pfizer announced that it is voluntarily withdrawing all lots of Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in all markets where it is available. Pfizer stated their decision is based on clinical data that shows that the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population.
According to the FDA, clinical trials conducted by Pfizer reported a higher rate of vaso-occlusive crisis (severe pain caused by sickled red blood cells blocking blood flow and oxygen delivery to tissues) in patients with sickle cell disease receiving Oxbryta compared to placebo. There were also more deaths in the Oxbryta treatment group as compared to the placebo group in these studies.
Reuters has reported that Pfizer is advising patients to contact their physicians to discuss alternative treatment, and that it would further review the available data and had notified regulatory authorities about its findings.
About the Lawsuit
If you or a loved one suffered extreme pain or death after taking the sickle cell disease drug Oxbryta, you may qualify for financial compensation. Fill out the form above to find out.
PAID ATTORNEY ADVERTISEMENT: This Webpage is a group advertisement. It is not a lawyer referral service. oxbrytaclaiminfo.com is owned and operated by Case Legal Media and is not a law firm. We connect people to legal service and there is no charge to be connected with an attorney. You are under no obligation to retain any services of those connected through our website. We try our best to keep things fair and balanced to help you make the best choice for you. This information does not constitute legal or medical advice and it should not be relied upon as such. Always consult with your doctor before modifying your medication or regular medical regimen.
